| Name | Title | Contact Details |
|---|
AIVITA Biomedical is a privately held company engaged in the advancement of commercial and clinical-stage programs utilizing curative and regenerative medicines.
FogPharma is dedicated to the creation of a new class of medicines that target human disease drivers currently considered `undruggable`.
Locana is a RNA-targeting gene therapy company
T-knife Therapeutics is a biopharmaceutical company dedicated to developing novel therapeutics to fight cancer, initially focused on T cell receptor (TCR) engineered T cell therapies (TCR-Ts), a modality that holds the potential to generate transformative responses in patients with solid tumors. The Company`s unique approach leverages its proprietary HuTCR mouse platform, a next-generation T cell receptor and epitope discovery engine that produces fully human, tumor-specific TCRs, naturally selected in vivo for optimal affinity and high specificity. T-knife is advancing a portfolio of TCR-T product candidates against targets with high unmet medical need, including cancer testis antigens, oncoviral antigens and commonly shared tumor-driving neoantigens. T-knife was founded by leading T-cell and immunology experts using technology developed at the Max Delbruck Center for Molecular Medicine together with Charité – Universitätsmedizin Berlin.
Oncoceutics Pharmaceuticals Inc is a Pittsburgh, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.